Stocks · News reference

bioAffinity Technologies shares are trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.

Oct 8, 2026, 4:02 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Oct 8, 2026, 4:02 PM
Checked: Oct 8, 2026, 4:02 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 13, 2026, 12:02 PMBenzinga Newsdesk
bioAffinity Technologies To Present New Data On Sputum-Based Tests In Development To Characterize Lung Inflammation And Detect Multiple Protein Biomarkers Of Lung Inflammation At CHEST 2026
Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targetsCompany advances research and development in diagnostic tests for major lung diseases
BIAF
BenzingaOct 8, 2026, 4:49 PMBenzinga Newsdesk
BIAF stock has given up its prior gain. bioAffinity Technologies shares were trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.
BIAF
BenzingaOct 8, 2026, 4:10 PMBenzinga Newsdesk
bioAffinity Technologies Commences ~$4M Offering Of Common Stock At $6.122 Per Share
BIAF